| HOME >> MEDICINE >> TECHNOLOGY |
Amortization of certain intangible assets reported in Cost of products sold resulting from acquisitions including Mayne Pharma, Javelin Pharma, and a generic injectable business by Hospira India.(B)
Impairment of certain assets reported in Restructuring, impairment and (gain) on disposition of assets, net resulting from intangible asset impairments of $7.5 million and equipment impairment of $7.1 million.(C)
Certain quality and product related charges reported in Cost of products sold primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review and remediation costs to address identified issues, and costs for corrective actions. These charges are primarily associated with Hospira's response to the FDA warning letter and charges related to certain device related remediation activities.(D)
Capacity expansion related charges reported in Cost of products sold include start-up charges related to manufacturing capacity expansion in India.(E)
Goodwill impairment related to the Europe, Middle East & Africa ("EMEA") reporting unit of $74.1 million and the Asia Pacific ("APAC") reporting unit of $171.1 million.(1)
Gross profit is defined
'/>"/>
| SOURCE Hospira, Inc. Copyright©2012 PR Newswire. All rights reserved |